Anti-osteoarthritis pharmaceutical composition and preparation method and application thereof

Abstract

The invention relates to an anti-osteoarthritis pharmaceutical composition and a preparation method and application thereof. The composition comprises the following components: male fern rhizome, glabrous greenbrier rhizome, amur cork-tree, baical skullcap root, rhubarb root and rhizome, bistort rhizome, figwortflower picrorhiza rhizome, and black alum. The composition selects raw materials basedon the theory of traditional Chinese medicine and the pathogenesis of osteoarthritis, follows the principle of mutual compatibility, and is scientific and reasonable in the ratio of each component. The osteoarthritis animal model and clinical observation and research shows that the pharmaceutical composition provided by the invention has the effects of tonifying the liver and kidney, and eliminating pathogenic factors and dampness, has the effects of preventing and treating osteoarthritis, and has no toxic and side effects after long-term administration.

Description

technical field [0001] The invention relates to the field of traditional Chinese medicine, in particular to an anti-osteoarthritis pharmaceutical composition and its preparation method and application. Background technique [0002] Osteoarthritis (OA) is a degenerative disease with joint pain as the main symptom, which is caused by fibrosis, chapped and ulcer loss of articular cartilage caused by various factors. It is the most common chronic progressive joint disease. The main clinical symptoms are joint pain, swelling, morning stiffness, joint effusion, joint hypertrophy, accompanied by bone friction, dysfunction or deformity during exercise. In particular, joint swelling manifests as early local swelling of the joint, including diffuse swelling of the joint, thickening of the synovial bursa, or joint effusion. Its etiology may be related to age, obesity, inflammation, trauma, and genetic factors. The pathological features are articular cartilage degeneration and destruct...

AI Technical Summary

Problems solved by technology

For end-stage OA, currently only surgical methods are available, such as artificial joint replacement, which usually requires high treatment costs and may cause complications

For patients with mid-stage OA, drug treatment is usually taken, including nonsteroidal anti-inflammatory drugs (NSAIDS), acetaminophen, tramadol and opioids, chondroitin sulfate and glucosamine, etc. These drugs can only play a role in relieving symptoms, but there is little evidence that these drugs can delay the progression of the disease; further, most of the above drugs have multiple side effects, and long-term use is toxic

There are also some new drugs or preparations to prevent OA, such as adalimumab (anti-TNF-α monoclonal antibody), tocilizumab (IL-6 receptor monoclonal antibody) and MOR-103 (anti-granulocyte-macrophage Colony-stimulating factor monoclonal antibody), these new drugs or preparations still have some problems: on the one hand, the results of clinical trials have shown that monoclonal antibody drugs cannot effectively relieve the pain of severe osteoarthritis; on the other hand, due to the high cost of treatment , making it unbearable for many patients, and it is difficult to promote and popularize the drug

Although Chinese medicine scholars have conducted a series of experimental studies on the treatment of OA with traditional Chinese medicine by using the results of modern clinical pathology and biochemical pharmacology research, and initially revealed the mechanism of the efficacy of traditional Chinese medicine in treating this disease, the therapeutic effect is still unsatisfactory.

Images